+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Omnitrope"

Somatotropin - Biosimilar Insight, 2022 - Product Thumbnail Image

Somatotropin - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Omnitrope is a brand of recombinant human growth hormone (rHGH) used to treat endocrine and metabolic disorders. It is used to treat growth failure in children and adults due to inadequate secretion of endogenous growth hormone, as well as to treat short stature associated with Turner Syndrome, Prader-Willi Syndrome, and chronic renal insufficiency. Omnitrope is also used to treat adult growth hormone deficiency, a condition in which the body does not produce enough growth hormone. Omnitrope is a biopharmaceutical product developed by Sandoz, a division of Novartis. It is approved for use in the United States, Europe, and other countries. Omnitrope is available in a variety of dosage forms, including vials, cartridges, and pre-filled pens. The Omnitrope market is highly competitive, with several companies offering similar products. These include Pfizer, Eli Lilly, Merck, and Novo Nordisk. Other companies in the market include Genentech, Ipsen, and Ferring Pharmaceuticals. Show Less Read more